ReviewCurrent neurology and neuroscience reports2016
Vaccines in Multiple Sclerosis.
Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04300868 (Immunisation Status Against Major Communicable Diseases Preventable With Vaccines, and Safety of Vaccines, in a Cohort of MS Patients. An Italian Multicenter Study), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunisation Status Against Major Communicable Diseases Preventable With Vaccines, and Safety of Vaccines, in a Cohort of MS Patients. An Italian Multicenter Study
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Nano-bio-encapsulation of phyto-vaccines: a breakthrough in targeted cancer immunotherapy.Molecular biology reports · 2024Review
- COVID-19 mRNA vaccination leading to CNS inflammation: a case series.Journal of neurology · 2022Article
- Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.Frontiers in neurology · 2022Review
- Pollution, Inflammation, and Vaccines: A Complex Crosstalk.International journal of environmental research and public health · 2021Review
- Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Vaccine-associated measles in a patient treated with natalizumab: a case report.BMC infectious diseases · 2020Article
- A matched case-control study of risk factors associated with multiple sclerosis in Kuwait.BMC neurology · 2020Article
- Article
- Immune response to vaccines is maintained in patients treated with dimethyl fumarate.Neurology(R) neuroimmunology & neuroinflammation · 2018Article
- Frequently asked questions on seven rare adverse events following immunization.Journal of preventive medicine and hygiene · 2017Review
- Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Deutsches Arzteblatt international · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccinations help prevent communicable disease. To be valuable, a vaccine's ability to prevent disease must exceed the risk of adverse effects from administration. Many vaccines present no risk of infection as they are comprised of killed or non-infectious components while other vaccines consist of live attenuated microorganisms which carry a potential risk of infection-particularly, in patients with compromised immunity. There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there has been concern that vaccination may trigger or aggravate the disease. Second, disease-modifying therapies (DMTs) employed in the treatment of MS may increase the risk of infectious complications from vaccines or alter their efficacy. Lastly, in some cases, vaccination strategies may be part of the treatment paradigm in attempts to avoid complications of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.